Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1987 1
1990 2
1991 1
1992 3
1993 1
1996 2
1998 1
1999 1
2006 1
2007 1
2014 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.
Salaun PY, Campion L, Ansquer C, Frampas E, Mathieu C, Robin P, Bournaud C, Vuillez JP, Taieb D, Rousseau C, Drui D, Mirallié E, Borson-Chazot F, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F. Salaun PY, et al. Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1501-10. doi: 10.1007/s00259-014-2772-0. Epub 2014 May 8. Eur J Nucl Med Mol Imaging. 2014. PMID: 24806110 Clinical Trial.
PURPOSE: PET is a powerful tool for assessing targeted therapy. Since (18)F-FDG shows a potential prognostic value in medullary thyroid carcinoma (MTC), this study evaluated (18)F-FDG PET alone and combined with morphological and biomarker evaluations as a surrogate …
PURPOSE: PET is a powerful tool for assessing targeted therapy. Since (18)F-FDG shows a potential prognostic value in medullary thyro …
Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.
Devys A, Thedrez P, Gautherot E, Faivre-Chauvet A, Saï-Maurel C, Rouvier E, Auget JL, Barbet J, Chatal JF. Devys A, et al. Int J Cancer. 1996 Sep 17;67(6):883-91. doi: 10.1002/(SICI)1097-0215(19960917)67:6<883::AID-IJC20>3.0.CO;2-1. Int J Cancer. 1996. PMID: 8824563 Free article.
We used MS of colorectal tumor cell lines expressing CEA strongly (LS 174T), weakly (HT-29) or not at all (HRT-18). Uptake and retention kinetics of 125I-F(ab)'2 F6 and 125I-BsMAb used alone gave similar results. The highest uptake values, obtained with LS 174T MS, were sl …
We used MS of colorectal tumor cell lines expressing CEA strongly (LS 174T), weakly (HT-29) or not at all (HRT-18). Uptake and retention kin …
Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Fiche M, Gautherot E, Barbet J, Chatal JF. Hosono M, et al. J Nucl Med. 1998 Sep;39(9):1608-13. J Nucl Med. 1998. PMID: 9744353 Free article.
Athymic mice inoculated with TT medullary thyroid cancer cells expressing CEA were administered BsMAbs F6-734, F6-679 or G7A5-734 and then, 48 hr later, 125I-di-DTPA-In hapten. Iodine-125-labeled F6 F(ab')2 fragment was injected into other groups of mice. Biodistributions …
Athymic mice inoculated with TT medullary thyroid cancer cells expressing CEA were administered BsMAbs F6-734, F6-679 or G7A5-734 and then, …
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F. Oudoux A, et al. J Clin Endocrinol Metab. 2007 Dec;92(12):4590-7. doi: 10.1210/jc.2007-0938. Epub 2007 Sep 18. J Clin Endocrinol Metab. 2007. PMID: 17878252 Clinical Trial.
Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: uptake, retention kinetics and dosimetric evaluation.
Bardiès M, Thedrez P, Gestin JF, Marcille BM, Guerreau D, Faivre-Chauvet A, Mahé M, Sai-Maurel C, Chatal JF. Bardiès M, et al. Int J Cancer. 1992 Apr 1;50(6):984-91. doi: 10.1002/ijc.2910500627. Int J Cancer. 1992. PMID: 1555897
The purpose of this study, using multi-cell spheroids as an in vitro model of micrometastases of ovarian carcinoma for i.p. radio-immunotherapy, was to measure the uptake and retention kinetics of 111In-labeled F(ab')2 fragments of OC125 monoclonal antibody (MAb) in sphero …
The purpose of this study, using multi-cell spheroids as an in vitro model of micrometastases of ovarian carcinoma for i.p. radio-immunother …
Reproducibility of image interpretation in immunoscintigraphy performed with indium-111- and iodine-131-labeled OC125 F(ab')2 antibody injected into the same patients.
Vuillez JP, Peltier P, Mayer JC, Dubois F, Chetanneau A, Fumoleau P, Bertrand A, Chatal JF. Vuillez JP, et al. J Nucl Med. 1991 Feb;32(2):221-7. J Nucl Med. 1991. PMID: 1992023 Free article.
Forty-six paired immunoscintigraphic examinations were performed on 43 patients with suspected ovarian carcinoma recurrence using F(ab')2 fragments of OC125 antibody labeled first with indium-111 and then with iodine-131. ...
Forty-six paired immunoscintigraphic examinations were performed on 43 patients with suspected ovarian carcinoma recurrence using F(a …
Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
Kraeber-Bodéré F, Faibre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thédrez P. Kraeber-Bodéré F, et al. J Nucl Med. 1999 Jan;40(1):198-204. J Nucl Med. 1999. PMID: 9935077 Free article.
The purpose of this study was to compare the toxicity and efficacy of two-step radioimmunotherapy using a bispecific anticarcinoembryonic antigen (CEA)/anti-diethylenetriamine pentaacetic acid (DTPA) antibody (F6-734 bispecific monoclonal antibodies (BsMAbs) and an 131I-di-DTPA-T …
The purpose of this study was to compare the toxicity and efficacy of two-step radioimmunotherapy using a bispecific anticarcinoembryonic an …
Immunoscintigraphy of recurrences of gynecologic carcinomas.
Chatal JF, Fumoleau P, Saccavini JC, Thedrez P, Curtet C, Bianco-Arco A, Chetanneau A, Peltier P, Kremer M, Guillard Y. Chatal JF, et al. J Nucl Med. 1987 Dec;28(12):1807-19. J Nucl Med. 1987. PMID: 3500284 Free article.
In a second, prospective study, 29 patients with gynecologic carcinoma were injected with 131I-OC 125 F(ab')2 (24) or 131I-19-9 F(ab')2 (5) MAbs according to the histologic type. ...Finally, in one patient injected successively with 131I-OC 125 F(ab')2 and 11 …
In a second, prospective study, 29 patients with gynecologic carcinoma were injected with 131I-OC 125 F(ab')2 (24) or 131I-19-9 F …
Pharmacokinetic study of radiolabeled anti-colorectal carcinoma monoclonal antibodies in tumor-bearing nude mice.
Douillard JY, Chatal JF, Saccavini JC, Curtet C, Kremer M, Peuvrel P, Koprowski H. Douillard JY, et al. Eur J Nucl Med. 1985;11(4):107-13. doi: 10.1007/BF00265042. Eur J Nucl Med. 1985. PMID: 4054153
The CRC/organ ratios and localization indices for both MoAbs increased with time in the CRC tissue, but remained low and unchanged in the melanoma and normal tissues. Using F(ab')2 antibody fragments, faster kinetics with earlier maximum accumulation, higher tumor/organ ra …
The CRC/organ ratios and localization indices for both MoAbs increased with time in the CRC tissue, but remained low and unchanged in the me …
17 results